Skip to main content

A platform company with dual exit optionality.

A near-term product de-risking a high-value pipeline. One platform powering two independent value creation paths.

For qualified investors and strategic partners only. No financial projections, specific fundraising amounts, or investment recommendations are made. This page may contain forward-looking statements; actual results may differ materially.

Why Plasfer

Plasfer sits at the intersection of an established, scalable biology (platelet medicine) and a large unmet need (precision oncology + regenerative medicine). The combination creates a business with multiple near-term catalysts and long-horizon upside.

Near-term regenerative revenues

PLA-REGEN targets the cash-pay aesthetic market first: high margin, no reimbursement risk, near-term visibility. Its regulatory classification is being defined with the competent authorities.

Self-funding pipeline logic

PLA-REGEN's revenues de-risk and partially fund the oncology pipeline — reducing capital requirements and investor dilution at each round. Both tracks advance on a single platform spend.

High-value oncology pipeline

PLA-CHEMO-1 and PLA-ONCO-1 target pancreatic cancer, one of the largest unmet needs in oncology (~$4.9B market in 2025). The same platform has pipeline optionality across GBM, breast cancer, and beyond.

Dual exit optionality

The regenerative business is a natural medtech or consumer-health M&A target. The oncology pipeline is a classic pharma licensing or co-development candidate. Investors access both on a single commitment.

Scientific leadership

Founded and led by Prof. Paolo Gresele (CSO), one of Europe's most-cited platelet biologists, alongside experienced management. Scientific Advisory Board includes Prof. Zaverio Ruggeri (Scripps) and other KOLs.

Request our investor deck

Qualified investors and strategic partners may request Plasfer's full corporate presentation, financial model, and programme data package. Please use the contact form and select "Investor" as your area of interest.

Request investor materials

Forward-looking statements

This page contains forward-looking statements regarding Plasfer's planned programmes, regulatory strategies, and business model. These statements involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied. Plasfer undertakes no obligation to update these statements. Nothing on this page constitutes an offer to sell, or a solicitation of an offer to buy, any securities.